A late phase II clinical trial of @entity12418 , a novel synthetic @entity4349 derivative anticancer agent, was conducted at 14 institutions nationwide, in @entity1 with @entity1893 . In this multi-center collaborative study, @entity632 was replaced by @entity12418 in @entity3726 therapy, a standard regimen for @entity1893 consisting of @entity786 , @entity632 , @entity1891 and @entity617 . A total of 39 @entity1 were enrolled in this study between January 1996 and March 1998. Among them, 37 @entity1 were eligible for this study. The study drugs were administered to @entity1 with @entity1893 according to the following schedule: @entity12418 (100 mg/m2, body surface area), @entity786 (750 mg/m2) and @entity1891 (1.4 mg/m2, a maximal dose of 2.0 mg/body) were administered intravenously on day one, while @entity617 (60 mg/m2/day) was administered orally on days 1 to 5. This cycle of treatment was repeated every three weeks in principle. The efficacy and safety were assessed for 37 eligible @entity1 . The combined rate for CR + CRu was 70.3% (26/37) and the overall response rate (CR + CRu + PR) was 86.5% (32/37). demonstrating that @entity12418 was very effective in the treatment of @entity1893 . The most frequent adverse reactions that occurred during the study were myelosuppressions: @entity1431 and @entity1398 , 100% (37/37); and decreases in hemoglobin levels, 81.1% (30/37). @entity882 , elevations of serum GOT and @entity6283 levels, @entity448 , @entity390 /vomitting, fever, @entity3136 and @entity1665 were also observed. Although @entity1431 and @entity1398 of grade 3 or higher were noted in 89.2% (33/37) and 94.6% (35/37), respectively, they were controllable by administrations of @entity1261 or solely by follow-up observations. One @entity1 developed @entity912 (grade 4) and another developed @entity6552 . In conclusion, these results indicate that @entity12418 is an effective agent as a component of combination chemotherapy for @entity1893 .

[Late phase II clinical study of XXXX , a novel synthetic @entity4349 derivative anticancer agent, for malignant lymphoma].

@entity1 :: ('9606', 'Species') :: ['patient', 'patients'] @entity12418 :: ('MESH:C055866', 'Chemical') :: ['amrubicin hydrochloride'] @entity632 :: ('MESH:D004317', 'Chemical') :: ['doxorubicin hydrochloride'] @entity1665 :: ('MESH:D000505', 'Disease') :: ['alopecia'] @entity390 :: ('MESH:D009325', 'Disease') :: ['nausea'] @entity3136 :: ('MESH:D013280', 'Disease') :: ['stomatitis'] @entity882 :: ('MESH:D013921', 'Disease') :: ['Thrombocytopenia'] @entity4349 :: ('CHEBI:48120', 'Chemical') :: ['anthracycline'] @entity6283 :: ('2875', 'Gene') :: ['GPT'] @entity1261 :: ('1440', 'Gene') :: ['G-CSF'] @entity3726 :: ('1649', 'Gene') :: ['CHOP'] @entity6552 :: ('MESH:D006396', 'Disease') :: ['hematemesis'] @entity786 :: ('MESH:D003520', 'Chemical') :: ['cyclophosphamide'] @entity448 :: ('MESH:D000855', 'Disease') :: ['anorexia'] @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia'] @entity1891 :: ('MESH:D014750', 'Chemical') :: ['vincristine sulfate'] @entity1431 :: ('MESH:D007970', 'Disease') :: ['leukopenia'] @entity1893 :: ('MESH:D008228', 'Disease') :: ["non-Hodgkin's lymphoma"] @entity912 :: ('MESH:D010243', 'Disease') :: ['intestinal paralysis'] @entity617 :: ('MESH:D011239', 'Chemical') :: ['prednisolone']
@entity12418 :: (MESH:C055866,Chemical) :: ['amrubicin hydrochloride']
